SCHEMBL1663099

SCHEMBL1663099

CC(C)c1nc2cc(O)ccc2c(=O)n1Cc1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.47
PIK3C2B O00750 1/20 0.46
MAPT P10636 3/20 0.44
HTT P42858 3/20 0.44
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
ALDH1A1 P00352 5/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX5AP P20292 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663885 0.87 ALOX5AP (0.52) TRPV1MAPTHDAC1HDAC6ALDH1A1
SCHEMBL1666102 0.81 TRPV1 (0.43) TRPV1PIK3C2BHTTHDAC1HDAC6
SCHEMBL1663953 0.79 TRPV1 (0.57) TRPV1MAPTHTTKDM4EALDH1A1
SCHEMBL1663625 0.78 TRPV1 (0.50) TRPV1MAPTHTTHDAC1HDAC6
SCHEMBL1663843 0.78 AKR1B1 (0.48) TRPV1MAPTHTTKDM4EALDH1A1
SCHEMBL1663421 0.77 TRPV1 (0.54) TRPV1HDAC1HDAC6ALDH1A1NPSR1
SCHEMBL1664148 0.77 TRPV1 (0.54) TRPV1MAPTHDAC1HDAC6ALDH1A1
SCHEMBL1663833 0.77 TRPV1 (0.47) TRPV1MAPTHTTHDAC1HDAC6
SCHEMBL1663509 0.76 TRPV1 (0.48) TRPV1MAPTHDAC1HDAC6KDM4E
SCHEMBL1663990 0.76 TRPV1 (0.47) TRPV1MAPTHDAC1HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885PIK3C2B 2455/4885MAPT 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.